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ABSTRACT
Purpose The aim of the current population pharmacokinetic
study was to quantify oxycodone pharmacokinetics in children
ranging from preterm neonates to children up to 7 years of
age.
Methods Data on intravenous or intramuscular oxycodone
administration were obtained from three previously published
studies (n= 119). The median [range] postmenstrual age of
the subjects was 299 days [170 days-7.8 years]. A population
pharmacokinetic model was built using 781 measurements of
oxycodone plasma concentration. The model was used to
simulate repeated intravenous oxycodone administration in
four representative infants covering the age range from an
extremely preterm neonate to 1-year old infant.
Results The rapid maturation of oxycodone clearance was
best described with combined allometric scaling and
maturation function. Central and peripheral volumes of dis-
tribution were nonlinearly related to bodyweight. The simu-
lations on repeated intravenous administration in virtual pa-
tients indicated that oxycodone plasma concentration can be
kept between 10 and 50 ng/ml with a high probability when
the maintenance dose is calculated using the typical clearance
and the dose interval is 4 h.
Conclusions Oxycodone clearance matures rapidly after
birth, and between-subject variability is pronounced in neo-
nates. The pharmacokinetic model developed may be used to
evaluate different multiple dosing regimens, but the safety of
repeated doses should be ensured.
KEY WORDS analgesic, opioid . infant, extremely
premature . oxycodone . pain . pharmacokinetics
ABBREVIATIONS
BDE Body weight dependent exponent
BSV Between-subject variability
CYP Cytochrome P450 enzyme
GA Gestational age
LLOQ Lower limit of quantification
NPDE Normalized prediction distribution errors
OFV Objective function value
PMA Postmenstrual age
PNA Postnatal age
PTA Probability of target attainment.
TVCL Typical clearance
WT Body weight
INTRODUCTION
Oxycodone is a pure semisynthetic opioid agonist that is
commonly used in adults and in the elderly for the treat-
ment of moderate and severe pain, and it is increasingly
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used also in children (1–3). A population pharmacokinetic
model of oxycodone has been built for infants and children
over 6 months of age, and a fixed weight-based dose has
been suggested (4).
The maturation of oxycodone pharmacokinetics is poorly
understood in infants less than 6 months of age, since only two
studies have been performed. In the first published study of
this age group (n= 22) no clear trend in the maturation was
observed because of marked between-subject variability (BSV)
(5). In a recent study (n = 76 including 64 infants under
6 months) of oxycodone and its metabolites in plasma and
urine, a clear trend in the maturation of oxycodone clearance
was found. This data suggested that extrarenal (hepatic) clear-
ance increases rapidly during the first months after birth
whereas renal clearance remains fairly low and constant (6).
In addition, the plasma concentrations of active metabolites,
oxymorphone and noroxymorphone, are very low and they
are not expected to contribute to the central opioid effects
based on the corresponding studies in older children and in
adults (7–9).
In the current study, a population pharmacokinetic model
of plasma oxycodone was built to describe the maturation of
oxycodone pharmacokinetics in infants and children including
preterm neonates. The data originated from the two studies
mentioned above (5,6) and a third study of oxycodone phar-
macokinetics of oxycodone in infants and children over sixth
months of age after intravenous (n = 9) and intramuscular
(n= 10) administration (10). The obtained model was used
to simulate oxycodone plasma concentration after repeated
intravenous dosing for different age groups to provide prelim-
inary dosing recommendations for further studies and clinical
work in small children.
METHODS
Data
Data were obtained from three studies (5,6,10). First, data on
intravenous oxycodone administration in infants were used
from a recent, optimally designed study (Study 1) (6). Most
subjects in this study received a single dose of oxycodone. If
the patient required hospital care for over 14 days or a read-
mission the approved study plan allowed studying oxycodone
pharmacokinetics for two or three times. Oxycodone was giv-
en to 79 infants, one infant received oxycodone three times
and six infants twice, and therefore, the total number of dosing
events was 87. After the exclusions (see 6), the total number of
infants, dosing events and oxycodone plasma concentrations
from Study 1 for the population pharmacokinetic modeling
were 76, 81 and 397, respectively.
Additionally, earlier published data from two trials were
used. The second dataset (Study 2) featured a total of 40
children aged between 6 months and 7 years, receiving a
single dose of oxycodone intravenously, intramuscularly, oral-
ly (via a gastric tube) or buccally (10). From those data, 19
subjects receiving oxycodone intravenously (n= 9) or intra-
muscularly (n= 10) were used. Data from oral and buccal
administration were excluded since BSV was significant for
these routes. The third dataset (Study 3) contained data for
a single intravenous oxycodone dose from a total of 24 neo-
nates and infants aged less than 6 months (5). The original
publication presented data only for 22 children since data
for one infant were too sparse for noncompartmental analysis
used in that study and another infant was aged over 6 months.
In all studies the dose was 0.1 mg/kg oxycodone hydro-
chloride trihydrate that corresponds to 0.087 mg/kg oxyco-
done hydrochloride and 0.078 mg/kg oxycodone base, re-
spectively. The studies are described in detail in the original
publications (5,6,10).
Analytical Methods
The oxycodone plasma concentrations are presented as free
base. In Study 1 oxycodone plasma concentration was quan-
tified using liquid chromatography-mass spectrometry with a
lower limit of quantification (LLOQ) of 0.2 ng/ml (6). The
samples from Study 2 were analyzed using gas chromatogra-
phy with mass spectrometric detection with a LLOQ of
1 ng/ml (10). Samples from Study 3 were analyzed with gas
chromatography with a LLOQ of 2 ng/ml (5).
Population Pharmacokinetic Analysis
General Description
Data were modeled with NONMEM version 7.3 (11). R ver-
sion 3.3.1 was used for data management and visualization
(12). The Perl-speaks-NONMEM software package was used
for run control (13). For comparisons between two nested
models, Likelihood Ratio Test was applied. This test consists
of comparing differences in Objective Function Value (OFV)
between nested models. The difference in OFV are asymptot-
ically chi-square distributed with the degrees of freedom
equaling the differences in number of parameters. For exam-
ple, an OFV difference of 6.63 with one extra parameter
corresponds to a p-value of 0.01. For comparisons between
two non-nested models, Akaike Information Criterion was
used. Furthermore, the choice betweenmodels was influenced
by the standard errors of parameter estimates, the presence or
lack of trends in residuals versus time, the presence or lack of
trends in random effects versus covariates, and the clinical in-
terpretability of the model.
Between-subject variability was described with lognormal
distributions as shown in Eq. 1:
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θi ¼ θ*exp ηið Þ ð1Þ
where ηi is distributed with a mean of zero and a standard
deviation of sd(ηi), which could be dependent on multiple
parameters.
Missing data were omitted from the analysis (M1 method)
(14) because for one of the studies (5), it was not always known
whether the missing data were caused by early termination of
sampling or by concentrations being below LLOQ. For re-
sidual variability, a combined additive and proportional error
(Eq. 2) was initially used, and residual error elements with
relative standard error less than 50% were retained in the
model. Separate residual errors were estimated for each
study.
yi j ¼ ipredi j* 1þ εprop
 þ εadd ð2Þ
where ε are distributed with a mean of zero and a standard
deviation of σ.
Covariate Model Development
Several models have been proposed to characterize drug
clearance maturation. Two of these approaches were tested,
namely body weight dependent exponent (BDE) and matura-
tion function based on postmenstrual age (PMA).
The BDE model features the prediction of typical clear-
ance (TVCL) by body weight (WT) raised to an exponent that
is itself a function of WT (Eqs. 3 and 4). Versions of this
function include Emax-type function (Eq. 5) (15) and exponen-
tial function (Eq. 6) (16).
TVCL ¼ θCL* WT=WTre fð ÞBDE ð3Þ
BDE ¼ f WT; θð Þ ð4Þ
f WT; θð Þ ¼ θ1−θ2*WTθ3= θ4θ3 þ WTθ3
  ð5Þ
f WT; θð Þ ¼ θ1*exp WT*θ2ð Þ ð6Þ
The PMA-based maturation function is typically combined
with scaling by WT with an exponent that is either estimated
or fixed to 0.75 (Eq. 7) (17).
TVCL ¼ θCL* WT=WTre fð Þθexp
* PMAHILL= θPMA50HILL þ PMAHILL
 
ð7Þ
The assumption in both of these models is that some mat-
uration of clearance pathways occurs in utero. Due to this
maturation, newborns already have some drug elimination
capacity at the moment of birth. The BDE model aims to
scale the clearance by WT, with an assumption that the ex-
ponent itself also varies as a function of WT (15,16).
As a null hypothesis, the volume of distribution was as-
sumed to scale linearly as a function of WT. This assumption
was challenged by estimating an allometric exponent for the
relationship between volume of distribution and WT (Eq. 8).
V ¼ θV* WT=4ð Þθexp ð8Þ
where θV is the volume of distribution for a typical infant of
4 kg and θexp is the exponent for the relationship between
volume of distribution and WT. A maturation function for
volume of distribution was also tested (17) (Eq. 9).
V ¼ θV WT=4ð Þ* 1þ θ1ð Þ*exp −θ2* WT−0:4ð Þð Þ ð9Þ
The equation is standardized so that the value of θ1 is esti-
mated for the lowest observed bodyweight (0.4 kg) within
Study 1 before patient exclusions.
Since BSV of clearance seemed in preliminary models to
be higher in neonates than in older children, the standard
deviation of clearance variability was modeled as a function
of postnatal age (PNA) (Eq. 10).
sd ηCL; ið Þ ¼ BSVbase þ BSVadd*exp −PNA*BSVexp
 
ð10Þ
where BSVbase is the baseline value of BSV, BSVadd is the
additional BSV at the PNA age of 0 days and BSVexp is the
exponent for the rate of decrease of additional BSV.
Model Evaluation
The final model was evaluated with a bootstrap based on
1000 resampled datasets. Normalized prediction distribution
errors (NPDE) were calculated based on 1000 simulations
(18). Agreement between observations and model predictions
was visually compared. Plots of the random effects of clear-
ance were plotted against covariates, for both model without
covariates and the final model with covariates.
Representative Dosing Simulations for Neonates
and Infants
The population pharmacokinetic model was used to simulate
repeated intravenous administration. Monte Carlo simula-
tions in four virtual patients were performed with an initial
dose of 0.1 mg/kg and subsequent maintenance doses of oxy-
codone hydrochloride trihydrate at i) every hour or ii) every
fourth hour to keep the average plasma concentration at the
assumed analgesic concentration of 25 ng/ml (19,20). The
maintenance dose was calculated using the typical clearance
of the virtual patient and the average target concentration.
The goal was to keep the oxycodone plasma concentrations
between 10 and 50 ng/ml, and the probability for achieving
this target concentration range was calculated.
The simulations were performed for four virtual patients:
1) an extremely preterm neonate with gestational age (GA) of
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182 days, PNA of 5 days, PMA 187 days, and WT of 0.5 kg
(e.g., ligature of the patent ductus arteriosus), 2) a modest/late
preterm neonate with GA 245 days, PNA 1 day, PMA
246 days, and WT 2.2 kg (e.g., herniotomy); 3) a term new-
born with GA 280 days, PNA 1 day, PMA 281 days, WT
3.5 kg (e.g., surgery for spina bifida) and 4) an infant aged
1 year with GA 280 days, PNA 365 days, PMA 644 days,
WT 10 kg (e.g., orchidopexy).
These simulated results can be used only for preliminary
dosing recommendations with close patient monitoring for
efficacy and safety since the safety of multiple dosing has not
been confirmed in infants and as BSV in pharmacokinetics
and –dynamics is significant.
RESULTS
Patients and Observations
The characteristics of the study population are shown in
Table I. The distribution of PMA, PNA and WT are shown
in a supplemental Figure S1. The observed data are shown in
Fig. 1, stratified by the study.
Population Pharmacokinetic Model
A two-compartmental model was applied to describe the time-
concentration data. Clearance was best predicted when it was
described as a function of PMA and WT, centered to a medi-
an patient of 4 kg (Eq. 7). The alternative model of exponen-
tially decreasing BDE (Eq. 6) had slightly worse fit to data
(dOFV= 31.8 with one parameter less). The parameter esti-
mates, their standard errors, and the bootstrap nonparametric
confidence intervals for the model with the PMA-based mat-
uration function are presented in Table II. Overall, the pa-
rameters were estimated with good precision. Bootstrap results
are based on 951 runs with successful minimizations out of
1000. The BSV of clearance was higher in neonates than in
older children (p< 0.001), when modeled according to Eq. 10.
Body weight adjusted volume of distribution was highest in
the smallest infants (p< 0.001). The decrease in WT-adjusted
central and peripheral volumes of distribution were best de-
scribed with the allometric power model (Eq. 8).
A good agreement between the observations and model
predictions was obtained (Fig. 2). Plots of NPDE versus time
and covariates showed no bias (Fig. 3). The typical parameter
values in the final model are described graphically in a sup-
plemental Figure S2, and so are the distribution of the random
effects (etas) for clearance and volume of distribution (supple-
mental Figures S3 and S4).
Representative Dosing Simulations
We simulated a loading dose of 0.1 mg/kg of oxycodone hy-
drochloride trihydrate and subsequent maintenance doses for
four virtual patients to keep the average oxycodone plasma
concentration at 25 ng/ml (Table III). The goal was to main-
tain oxycodone plasma concentrations between 10 and
50 ng/ml. The probability for maintaining oxycodone con-
centration within this range was approximately 90% with 1-h
dose interval (Fig. 4). The probability was over 70% with 4-h
dose interval except for the 1-year old infant with the shortest
elimination half-life (Fig. 4). The elimination half-life of oxy-
codone is significantly longer in typical neonates than in older
infants because of relatively lower clearance and relatively
higher volume of distribution (Table III). This reduces the
fluctuation of oxycodone plasma concentration within the
dose interval, even though the unexplained BSV of clearance
is highest in the neonates.
DISCUSSION
We have studied the developmental pharmacokinetics of oxy-
codone starting from extremely pretermneonates up to 7 years
old children. Elucidating the developmental pharmacokinetics
within the first 6 months of life is particularly important be-
cause many of the pharmacokinetic changes typically occur
during this period (15–17,21). The majority of our pharma-
cokinetic data came from the recent study with sparse blood
sampling (6). These data were supplemented by two earlier
published studies with dense sampling (5,10). Combined,
these datasets form a robust basis for a population pharmaco-
kinetic model. Until present, a developmental pharmacokinet-
ic model of oxycodone was available only for children older
than 6 months of age (4).
Table I Patient Demographics
Study 1 (6) Study 2 (10) Study 3 (5)
Subjects/samples (n) 76/397 19/200 24/184
Bodyweight (kg) 4 (0.52–14; 3.27) 13 (8–34; 8.13) 3.9 (1.8–9.3; 1.95)
Postnatal age (days) 39.5 (0–650; 156) 960 (240–2580; 773) 21 (1–298; 76)
Postmenstrual age (days) 300 (170–930; 168) 1240 (520–2860; 773) 299 (232–578; 83.3)
Data are number of subjects/samples for the first row, and median (range; standard deviation) for the remaining rows
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During modeling, we tested two approaches to scale clear-
ance as a function ofWT or PMA: BDEmodel (15,16,21) and
the maturation function based on PMA (17). The latter
approach described our data slightly better, and the model
parameters were estimated with high precision. This is in
agreement with previous studies which have shown that the
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Fig. 1 Oxycodone plasma
concentrations in Studies 1 (a), 2
(b), and 3 (c). The dose was
0.1 mg/kg oxycodone
hydrochloride trihydrate
(0.087 mg/kg oxycodone
hydrochloride) intravenously except
ten of nineteen subjects in Study 2
received the same dose
intramuscularly. Original sources:
Study 1 (6), Study 2 (10), and Study
3 (5).
Table II The Parameter Estimates of the Model
Symbol Description Estimate RSE Bootstrap
5th %
Bootstrap
95th %
Clearance:
CLi = θ1*(WT/4)
θ2*PMAθ3/(PMAθ3+ θ4
θ3)*exp(ηCL,i)
Where ηCL is distributed with mean of zero,
and standard deviation of
sd(ηCL,i) = θ5+ θ6*exp(−PNA*θ7)
θ1 Clearance (L/h) for a fully mature 4 kg infant 4.60 9% 4.01 5.36
θ2 Exponent for clearance scaling by bodyweight 0.75 FIX – – –
θ3 Hill coefficient for clearance maturation 3.82 9% 3.26 4.60
θ4 Postmenstrual age at which clearance is 50%
mature (d)
303 6% 271 332
θ5 Baseline standard deviation of CL variance 0.307 19% 0.00307 0.404
θ6 Increase in BSV CL at postnatal age of zero 0.297 26% 0.198 0.604
θ7 Exponent for decrease in clearance variability
(1/d)
0.00440 39% 0.000465 0.00814
Central Vd:
Vc,i = θ8 * (WT/4)
θ10 * exp(ηVc,i)
Peripheral Vd:
Vp,i = θ9 * (WT/4)
θ10 * exp(ηVp,i)
θ8 Central Vd (L) for an infant of 4 kg 5.23 6% 4.70 5.76
θ9 Peripheral Vd (L) for an infant of 4 kg 5.91 7% 5.29 6.61
θ10 Exponent for V scaling by bodyweights 0.861 10% 0.718 0.997
θ11 Correlation for random effects of CL and Vd 0.743 7% 0.639 0.825
θ12 Standard deviation of ηVc,i 0.537 11% 0.433 0.644
θ13 Standard deviation of ηVp,i 0.511 12% 0.398 0.608
Inter-compartmental clearance:
Qi = θ14*(WT/4)
θ10
θ14 Intercompartmental clearance for an infant
of 4 kg (L/h)
22.0 13% 18.1 27.6
Absorption rate constant of intramuscular injection:
ka,i = θ15 *exp(ηka,i)
Bioavailability of intramuscular injection:
θ16
θ15 ka for intramuscular injection (1/h) 7.56 28% 4.83 12.5
θ16 Bioavailability of intramuscular injection 0.903 11% 0.768 1.16
ωka Standard deviation of ηka,i 0.79 35% 0.0079 1.19
Residual error σ1 Proportional error, Study 3 (%) 16 8.6% 13 18
σ2 Additive error, Study 3 (ng/mL) 0.29 33% 0.0029 0.44
σ3 Proportional error, Study 2 (%) 15 8.3% 13 17
σ4 Additive error, Study 2 (ng/mL) 0.49 10% 0.42 0.62
σ5 Proportional error, Study 1 (%) 17 11% 13 20
BSV between-subject variability; CL elimination clearance; ka absorption rate constant; PMA postmenstrual age; PNA postnatal age; Q intercompartmental
clearance; RSE relative standard error; Vc central volume of distribution; Vp peripheral volume of distribution; Vd volume of distribution; WTweight
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developmental pharmacokinetics of drugs metabolized by
CYP3A enzymes, as is the case also for oxycodone (6,7), can
be described with both modeling approaches.
Our data show that the WT-adjusted clearance of oxyco-
done is lowest in preterm neonates (Table III). On the other
hand, the WT-adjusted apparent volume of distribution is
highest in this age group. The opposite changes in these
WT-adjusted variables with age and WT resulted in marked
differences in the elimination half-life with typical values
ranging between 8 h in extremely preterm neonates and 2 h
in infants over 6 months of age.
The maturation of oxycodone clearance within the first
months of life seems to be similar to that observed for some
other drugs (15–17). Correspondingly, altered volume of dis-
tribution in newborns compared to other age groups has also
been documented for morphine (22) and paracetamol
(acetaminophen) (23). This difference is likely due to the dif-
ferent body composition of the newborns.
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Fig. 3 Normalized prediction
distribution errors (NPDE) versus
time after drug administration (a),
body weight (b), postnatal age
(PNA) (c) and postmenstrual age
(PMA) (d). The model is unbiased if
no systematic trends are seen in the
distribution errors (y-axis) versus the
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Table III Pharmacokinetic Parameters for the Virtual Patients
Patient Postmenstrual
age (days)
Weight (kg) CL (l h−1 kg−1) Vss (l/kg) T1/2 (h) Dose1h (μg/kg) Dose4h (μg/kg)
Extremely preterm neonate 187 0.5 0.26 3.7 9.9 10 35
Modest/late preterm neonate 246 2.2 0.42 3.0 5.2 15 55
Term neonate 281 3.5 0.51 2.8 4 15 65
Infant aged 1 year 644 10.0 0.87 2.5 2.1 25 110
CL elimination clearance; Vss apparent volume of distribution at steady state (the sum of central and peripheral volumes); T1/2 elimination half-life; Dose1h
Individualized dose for dosing hourly to keep the average plasma concentration at 25 ng/ml; Dose4h Individualized dose for dosing every fourth hour to keep the
average plasma concentration at 25 ng/ml. The doses are reported as oxycodone hydrochloride trihydrate and they are rounded to the nearest value that is
divisible by five. The dose can be converted to oxycodone base or oxycodone hydrochloride by multiplying the dose by 0.78 or 0.87, respectively
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Fig. 4 Simulated oxycodone plasma concentrations for repeated intravenous administration. The loading dose is 0.1 mg/kg oxycodone hydrochloride trihydrate,
and maintenance doses are subsequently administered hourly (a–h) or at every fourth hour (i–p) to keep the average concentration at 25 ng/ml (see Table III).
The four panel columns from left to right correspond to the four representative patients; an extremely preterm neonate, a late preterm neonate, a term neonate,
and an infant aged 1 year, respectively. In panels (a–d) and (i–l), the black solid lines are population predictions without variability and gray, transparent areas are the
5–95% percentiles and 25–75% percentiles of simulated values for 200 virtual patients, respectively. Panels (e–h) and (m–p) show the probability of maintaining
the target concentration between 10 and 50 ng/ml for the respective patients. PMA postmenstrual age, PTA probability of target attainment.
Oxycodone in Neonates and Infants 1131
We utilized the model to simulate repeated intravenous
oxycodone doses in four clinically relevant scenarios (Fig. 4).
These simulations reveal the key features in oxycodone phar-
macokinetics in neonates and infants. First, the increased BSV
at first days of life can be seen in the youngest virtual patients.
Second, the decrease in elimination half-life can be seen with
increasing PMA and WT. This decrease in elimination half-
life results both from increasing clearance and decreasing rel-
ative volume of distribution.
The maintenance doses calculated using typical clearance
(Table III) keep oxycodone plasma concentration of virtual
patients between 10 and 50 ng/ml most of the time with 1-h
dose interval (Fig. 4). The probability for maintaining the
concentration within this range decreases with 4-h dose inter-
val, especially for the 1-year old infant with the short elimina-
tion half-life. The analgesic concentration of oxycodone in
infants has not been established. Based on data in 18 healthy
children having ophthalmic surgery under halothane anesthe-
sia, a minimum analgesic concentration of 12 ng/ml was pro-
posed (20). In adults with laparoscopic cholecystectomy amin-
imum effective concentration of 20–30 ng/ml has been pre-
sented (19). In case reports of oxycodone intoxication in chil-
dren plasma oxycodone concentrations have been significant-
ly higher, 600–1360 ng/ml (24,25). Thus, the oxycodone plas-
ma concentration of 10–50 ng/ml used in these simulations
could be considered appropriate. However, because of the
large randomBSV in oxycodone pharmacokinetics quantified
in the current study and the expected large variability in oxy-
codone pharmacodynamics, individual dose titration is war-
ranted. These simulation results should be considered as pre-
liminary proposals, and oxycodone, as all opioid analgesics,
should be administered with caution before further efficacy
and safety data in pediatric patients are available.
Furthermore, the safety of repeated oxycodone doses remains
to be evaluated in this population.
CONCLUSION
We have quantified the developmental pharmacokinetics of
oxycodone and proposed initial dose recommendation for ini-
tial titration of oxycodone analgesia in small children.
However, as between-subject variability in pharmacokinetics
appears to be pronounced, close follow-up for efficacy and
safety is warranted especially in preterm and newborns.
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